Document is current
Any future updates will be listed below
-
Authors
Qian, Men-Bao
Zhao, Jia-Guang
Han, Xiao-Ping
Liu, Liu
Zhou, Chang-Hai
Huang, Ji-Lei
Zhu, Yu-Ying
Gan, Xiao-Qin
Meng, Jun
Li, Shi-Zhu
-
Funding
Funding for this research was provided by:
National Disease Control and Prevention Administration
National Natural Science Foundation of China (82373645)
Shanghai Talent Program
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 15 July 2026
First Online: 20 July 2026
Declarations
Ethics approval and consent to participate: The study was approved by the Ethical Review Committee of National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research) (ref: 2024-009). This trial was registered with on 27 February 2025, number ISRCTN46268871 ( ). The study was conducted in accordance with the Declaration of Helsinki. Written informed consents were obtained from all participants. After the study, the participants who remained positive after treatment, or who were positive but excluded due to exclusionary criteria (except for pregnant women or the individuals with other contraindications) were provided with praziquantel (25 mg/kg 3 times daily for 1 day) free.
Consent for publication: Not applicable.
Competing interests: The authors declare no competing interests.
